<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311554</url>
  </required_header>
  <id_info>
    <org_study_id>ADHOC-1001</org_study_id>
    <nct_id>NCT04311554</nct_id>
  </id_info>
  <brief_title>Aging With Dignity, Health, Optimism and Community</brief_title>
  <acronym>ADHOC</acronym>
  <official_title>Aging With Dignity, Health, Optimism and Community</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazonson &amp; Santas Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peter Shalit MD and Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Red River Family Practice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Texas Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rosedale Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Midland Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anthony Mills MD Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Whitman-Walker Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruth M. Rothstein CORE Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UW Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mazonson &amp; Santas Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ADHOC is an observational study of people living with HIV over the age of 50. Data from this
      study will be used to research the interaction between HIV and aging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADHOC is an observational study that collects data on PLWH over the age of 50 using an online
      questionnaire. The questionnaire includes information on sociodemographic factors, activities
      and interests, HIV diagnosis and status, health care use and satisfaction, antiretroviral
      therapy, comorbid medical conditions, health and well-being, substance use, and sexual
      practices.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">October 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 19, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in loneliness</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Three-Item Loneliness Scale. This scale is comprised of 3 questions that measure three dimensions of loneliness: relational connectedness, social connectedness and self-perceived isolation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Loneliness at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Three-Item Loneliness Scale. This scale is comprised of 3 questions that measure three dimensions of loneliness: relational connectedness, social connectedness and self-perceived isolation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the PozQoL. PozQoL is a short 13-question scale assessing quality of life among people living with HIV. The scale includes four subscales: health concerns, psychological, social and functional.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the PozQoL. PozQoL is a short 13-question scale assessing quality of life among people living with HIV. The scale includes four subscales: health concerns, psychological, social and functional.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in cognitive function</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Functional Assessment of HIV Infection (FAHI Cognition). The FAHI Cognition subscale will be used to create a standardized score to assess outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cognitive function at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Functional Assessment of HIV Infection (FAHI). The FAHI Cognition subscale will be used to create a standardized score to assess outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in social well-being</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Functional Assessment of HIV Infection (FAHI). The FAHI Social Well-being subscale will be used to create a standardized score to assess outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Social well-being at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Functional Assessment of HIV Infection (FAHI). The FAHI Social Well-being subscale will be used to create a standardized score to assess outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depression</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Patient Health Questionnaire - 4 (PHQ-4). PHQ-4 is a brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Patient Health Questionnaire - 4 (PHQ-4). PHQ-4 is a brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anxiety</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Patient Health Questionnaire - 4 (PHQ-4). PHQ-4 is a brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anxiety at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Patient Health Questionnaire - 4 (PHQ-4). PHQ-4 is a brief self-report questionnaire that consists of a 2-item depression scale (PHQ-2) and a 2-item anxiety scale (GAD-2).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in sleep quality</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using The Medical Outcomes Study Sleep Scale (MOS-SS). MOS-SS includes 12 items assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep quality at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using The Medical Outcomes Study Sleep Scale (MOS-SS). MOS-SS includes 12 items assessing sleep disturbance, sleep adequacy, somnolence, quantity of sleep, snoring, and awakening short of breath or with a headache.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in alcohol use</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Alcohol Use Disorder Identification Test (AUDIT-C). The AUDIT-C is a 3-item screening survey that can help identify persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alcohol use at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Alcohol Use Disorder Identification Test (AUDIT-C). The AUDIT-C is a 3-item screening survey that can help identify persons who are hazardous drinkers or have active alcohol use disorders (including alcohol abuse or dependence).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in self-perceived stigma</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Internalized AIDS-Related Stigma scale (IAS). IAS is a six-item scale designed to measure the construct of internalized stigma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Self-perceived stigma at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Internalized AIDS-Related Stigma scale (IAS). IAS is a six-item scale designed to measure the construct of internalized stigma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in lipodystrophy</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Assessment of Body Change and Distress (ABCD). The ABCD assesses subjective report of bodily changes and body dissatisfaction, and it includes 20 items on the impact of bodily changes on psychosocial variables, quality of life, and HIV self-care behaviors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipodystrophy at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Assessment of Body Change and Distress (ABCD). The ABCD assesses subjective report of bodily changes and body dissatisfaction, and it includes 20 items on the impact of bodily changes on psychosocial variables, quality of life, and HIV self-care behaviors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in resilience</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Connor-Davidson Resilience Scale (CD-RISC 2). The CD-RISC contains two items and was developed as a measure of &quot;bounce-back&quot; and adaptability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Resilience at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Connor-Davidson Resilience Scale (CD-RISC 2). The CD-RISC contains two items and was developed as a measure of &quot;bounce-back&quot; and adaptability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in interpersonal support</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Interpersonal Support Evaluation Checklist - 6 (ISEL-6). ISEL-6 is derived from the long form of the ISEL and contains 6 items that assess the perceived availability of social support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Interpersonal support at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Interpersonal Support Evaluation Checklist - 6 (ISEL-6). ISEL-6 is derived from the long form of the ISEL and contains 6 items that assess the perceived availability of social support.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in anti-HIV medication adherence</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the brief adherence self-report questionnaire. This questionnaire asks participants how much of their anti-HIV medications they have taken over the past month (0 to 100%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Anti-HIV medication adherence at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the brief adherence self-report questionnaire. This questionnaire asks participants how much of their anti-HIV medications they have taken over the past month (0 to 100%).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in frailty</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Measured using the Frailty Index Elders (FIFE). FIFE is a 10-item instrument with scores ranging from 0-10. A score of 0 indicates no frailty; a score of 1-3 indicates frailty risk; and a score of 4 or greater indicates frailty.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frailty at baseline</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Frailty Index Elders (FIFE). FIFE is a 10-item instrument with scores ranging from 0-10. A score of 0 indicates no frailty; a score of 1-3 indicates frailty risk; and a score of 4 or greater indicates frailty.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic characteristics</measure>
    <time_frame>Baseline, and once a year through study completion.</time_frame>
    <description>Demographic characteristics including, but not limited to, age, sex, race, body weight, income, and education will be evaluated as potential predictors of inter- and intra-participant variability for patient-reported outcome measures.</description>
  </secondary_outcome>
  <enrollment type="Actual">1049</enrollment>
  <condition>HIV</condition>
  <eligibility>
    <study_pop>
      <textblock>
        People over the age of 50 with an HIV-1 or -2 infection.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligibility criteria:

          -  have an HIV-1 or -2 infection,

          -  be ≥ 50 years of age,

          -  have no known acute medical problems requiring immediate inpatient treatment,

          -  be able to read and write in English, and

          -  be able and willing to provide online informed consent and complete the profile
             online.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mazonson &amp; Santas Inc</name>
      <address>
        <city>Larkspur</city>
        <state>California</state>
        <zip>94939</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>PLWH</keyword>
  <keyword>Aging</keyword>
  <keyword>Older</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 2, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04311554/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

